lfvn-20220217

0000849146-22-000015.txt : 20220217 0000849146-22-000015.hdr.sgml : 20220217 20220217160608 ACCESSION NUMBER: 0000849146-22-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220217 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220217 DATE AS OF CHANGE: 20220217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 22648079 BUSINESS ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-20220217.htm 8-K lfvn-20220217

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________

FORM 8-K

______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2022

______________________________

LIFEVANTAGE CORPORATION

(Exact name of registrant as specified in its charter)

______________________________

Delaware

001-35647

90-0224471

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(IRS Employer
Identification No.)

3300 Triumph Blvd, Suite 700

Lehi, Utah 84043

(Address of principal executive offices, including zip code)

(801) 432-9000

(Registrant's telephone number)

_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, par value $0.0001

LFVN

The Nasdaq Stock Market LLC

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02			Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 17, 2022, the Board of Directors (the “Board”) of LifeVantage Corporation (the “Company”), based on the recommendation of the Board’s Nominating and Corporate Governance Committee, authorized and approved (i) the appointment of Cynthia Latham as a member of the Board and (ii) the appointment of Ms. Latham to the Compensation Committee, effective immediately. Ms. Latham’s term will expire at the fiscal 2023 annual meeting of stockholders. The Company issued a press release announcing the appointment of Ms. Latham. A copy of that press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.

The Company’s non-employee director compensation program for fiscal 2022 provides for a monthly cash retainer of $5,000 for service on the Board. Additionally, the Company’s non-employee director compensation program provides new non-employee directors an initial restricted stock award for a number of shares equal to $75,000 divided by the average closing price of the Company’s common stock for each of the ten trading days ending the day before the date such new non-employee director is first appointed to the Board. The number of shares issued under the restricted stock award to Ms. Latham has been pro-rated for the number of months until the expected date of the Company’s fiscal 2023 annual meeting of stockholders. This initial restricted stock award will vest in full on the one year anniversary of Ms. Latham’s appointment to the Board, subject to her continued service through such date.

The Company also entered into an Indemnification Agreement with Ms. Latham. The Indemnification Agreement provides for indemnification and advancement of litigation and other expenses to Ms. Latham to the fullest extent permitted by law for claims relating to her service to the Company or its subsidiaries. The Company’s form of indemnification agreement was filed with the SEC on March 13, 2018 as Exhibit 99.1 to the Company’s Current Report on Form 8-K and is incorporated herein by reference.

There are no family relationships between Ms. Latham and any of the Company’s directors or executive officers and Ms. Latham does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Ms. Latham was named a director.


Item 9.01			Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description
99.1						Press Release issued by the Company on February 17 , 202 2 announcing appointment of C indy Latham to the Board of Directors.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




Date:	February 17, 2022	LIFEVANTAGE CORPORATION

	By:	/s/ Steven R. Fife
	Name:	Steven R. Fife
	Title:	President and Chief Executive Officer

EX-99.1 2 exhibit991pressrelease-lat.htm EX-99.1 Document

LifeVantage Appoints Cindy Latham to Board of Directors

Salt Lake City, UT, February 17, 2022, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Cindy Latham to the Company's Board of Directors. Latham is a senior-level marketing executive with over 30 years of experience leading global marketing, research and development, and product teams in direct selling organizations.

Garry Mauro, Chairman, said of the appointment: "We are delighted to welcome Cindy to the LifeVantage Board. She is a proven leader with outstanding industry experience and a strong track record of driving growth.”

“It’s an honor to join the Board at this time, to help shape new strategies and tactics that leverage the incredible power of the LifeVantage brand across a global network of distributors and customers,” said Latham. “With a talented leadership team, strong foundation and unique product platform, the Company is well positioned for growth.”

About Cindy Latham

Cindy currently serves as Executive Marketing Consultant at Latham Consulting Services, a strategic marketing consulting firm. She has over 30 years of experience leading global marketing, research and development, and product teams in direct selling organizations. Prior to Latham Consulting Services, Cindy served as Chief Marketing Officer at Plexus Worldwide, where she developed the branding strategy and led the full rebranding of the company. She also built an award-winning marketing, research and development organization and drove significant revenue growth. Her previous experience includes 17 years at Shaklee Corporation, most recently as Senior Vice President of Global Marketing, where she was responsible for marketing, new product development, corporate branding, market research, creative services, business development, and environmental and sustainability initiatives.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+™, ProBio™, and Daily Wellness™ dietary supplements, TrueScience® is the Company's line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Investor Relations Contact:

Reed Anderson, ICR

(646) 277-1260

reed.anderson@icrinc.com

EX-101.SCH 3 lfvn-20220217.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lfvn-20220217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 lfvn-20220217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image.jpg begin 644 image.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Oct. 25, 2021
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 17, 2022
Entity Registrant Name	LIFEVANTAGE CORP
Entity Central Index Key	0000849146
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35647
Entity Tax Identification Number	90-0224471
Entity Address, Address Line One	3300 Triumph Blvd
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	432-9000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	LFVN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 lfvn-20220217_htm.xml IDEA: XBRL DOCUMENT 0000849146 2021-10-25 2021-10-25 0000849146 false 8-K 2022-02-17 LIFEVANTAGE CORP DE 001-35647 90-0224471 3300 Triumph Blvd Suite 700 Lehi UT 84043 801 432-9000 false false false false Common Stock, par value $0.0001 LFVN NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lifevantage.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lfvn-20220217.htm exhibit991pressrelease-lat.htm lfvn-20220217.xsd lfvn-20220217_lab.xml lfvn-20220217_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lfvn-20220217.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "lfvn-20220217.htm" ] }, "labelLink": { "local": [ "lfvn-20220217_lab.xml" ] }, "presentationLink": { "local": [ "lfvn-20220217_pre.xml" ] }, "schema": { "local": [ "lfvn-20220217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lfvn", "nsuri": "http://www.lifevantage.com/20220217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20220217.htm", "contextRef": "ia2bdf58e55e84a6bb68333253cb22f46_D20211025-20211025", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lifevantage.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20220217.htm", "contextRef": "ia2bdf58e55e84a6bb68333253cb22f46_D20211025-20211025", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000849146-22-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000849146-22-000015-xbrl.zip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end